Head and Neck Cancer Biomarkers
AssigneeWilliam Beaumont Hospital
InventorsJAN A. AKERVALL, Bryan J. Thibodeau, George D. Wilson
Life of this patent
Estimating the term…
Abstract
A method for predicting the response to treatment in a patient suffering from a head or neck cancer including: obtaining a biological sample for the patient; measuring the expression level of several gene and using the measurement to predict a patient's response to treatment. The methods may include predicting the treatment response in a patient having virally-induced head or neck cancer; and/or using the prediction to treat the patient.
Claims20
A method for predicting the response to treatment in a patient and or a method of treating a patient suffering from a head or neck tumor comprising:
- a) obtaining a biological sample of said tumor from said patient;
- b) measuring one or more of the protein, mRNA, or cDNA levels of at least one biomarker in said sample to obtain a biomarker measurement, wherein said biomarker is selected from the group consisting of
- (a) LCE3D;
- (b) KRTDAP;
- (c) HMOX1;
- (d) KRT19;
- (e) MDK;
- and
- (f) TSPAN1;
- in any combination thereof;
- and using the measurement to predict a patient's response to treatment.
The method of making a treatment recommendation for a patient suffering from a head or neck tumor comprising:
- a) obtaining a biological sample of said tumor from said patient;
- b) measuring one or more of the protein, mRNA, or cDNA levels of at least one biomarker in said sample to obtain a biomarker measurement, wherein said biomarker is selected from the group consisting of
- (a) LCE3D;
- (b) KRTDAP;
- (c) HMOX1;
- (d) KRT19;
- (e) MDK;
- and
- (f) TSPAN1;
- in any combination thereof;
- and using said measurement to make a recommendation for treatment in said patient when any one or more of biomarkers (a-c), or any combination of biomarkers (a-c), indicate gene upregulation in said sample and/or any one or more of biomarkers (d-f), or any combination of biomarkers (d-f), indicate gene downregulation in said sample.
A method for prognosis, or evaluation of the effectiveness of a treatment, of a solid tumor in a patient of interest, wherein said tumor is a HNSCC and said method of evaluation comprises obtaining a sample of said HNSCC, then determining whether said patient has a HPV-positive HNSCC, then further determining whether said patient will respond favorably to chemo or radiotherapy using the method for predicting the response to treatment, method of making a treatment recommendation, and the method of treatment is known to one skilled in the art, and includes the option, when the HNSCC is determined to be HPV-positive HNSCC, then the patient is selected for “therapy de-escalation” including treatments that do not include chemoradiation.
A method of determining a prognosis of cancer characterized by analysis of a sample comprising the following steps:
- a) determine if the sample is HPV-positive HNSCC or HPV-negative HNSCC;
- and if the sample is HPV-positive HNSCC then;
- b) determine whether the patient is likely or not likely to benefit from traditional therapy and wherein said determination is made based on whether or not at least one biomarker from the following group is obtained from the patient's tumor and where the biomarkers is said to be upregulated with biomarkers
- (a) LCE3D;
- (b) KRTDAP;
- (c) HMOX1;
- and downregulated in biomarkers selected from the group consisting of (d-f):
- (d) KRT19;
- (e) MDK;
- and
- (f) TSPAN1
- where said biomarkers may be in any number or combination or may be only those as described exactly above as (a)-(f).
Dependencies are inferred from the claim text.